VEGFA and renal carcinoma: In addition, results for people who have only had prior cytokines are less relevant to clinical practice than for prior VEGF-targeted treatments as most people receive a TKI first line, in line with clinical guidelines.12 The NMAs of Amzal et al39 and Rassy et al40 are also limited by the reliance on the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) trial41 to link axitinib and sorafenib to the network analysed.